Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)

In conclusion, most TRACER participants were treated with low-dose ASA, although a high dose was common in North America. High-dose participants tended to have higher rates of ischemic and bleeding outcomes. Although formal statistical testing did not reveal heterogeneity in vorapaxar's effect across dose subgroups, consistent trends support use of low-dose ASA with other antiplatelet therapies.

Source: The American Journal of Cardiology - December 26, 2013 Category: Cardiology Authors: Kenneth W. Mahaffey, Zhen Huang, Lars Wallentin, Robert F. Storey, Lisa K. Jennings, Pierluigi Tricoci, Harvey D. White, Paul W. Armstrong, Philip E. Aylward, David J. Moliterno, Frans Van de Werf, Edmond Chen, Sergio Leonardi, Tyrus Rorick, Claes Held, J Tags: Coronary Artery Disease Source Type: research